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Abstract
Context. Acromegaly is a rare and
serious syndrome and commonly associated
with pituitary neoplasm. Classic cause of
acromegaly in adults is the tumors of the
somatotrophs that secrete growth hormone.
Cirrhosis is the end stage of chronic liver
disease and commonly a cause of death. It is
characterized by diffuse hepatic fibrosis
resulting in altered construction of the
lobular parenchyma with widespread
connective tissue septae, circumscribed
regenerative nodules of hepatocytes and
anastomoses between vascular channels
linking portal and central vessels. 
Objective. To report the simultaneous
cases of acromegaly and cirrhosis.
Case report. A 62-year old, male
patient came to the hospital complaining of
severe abdominal swelling. Laboratory and
imaging findings were compatible with the
presence of hepatitis B virus related
cirrhosis together with acromegaly. In this
case, he had high GH level but lower IGF-1
level because of hepatic failure which can
impair IGF-1 production by the liver.
Definitive diagnosis was made by pituitary
MR and a 1 cm in diameter tumor was
detected.
Conclusion. This paper showed that
cirrhosis can result in a low IGF-I level in
patients with acromegaly. There is no
previous report available of the in the
presence of coincidental combination of
acromegaly and cirrhosis in a patient. 
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INTRODUCTION 
Acromegaly is a syndrome
characterized by the release of excessive
amounts of growth hormone (GH) and
insulin-like growth factor (IGF-1). The
mean age of diagnosis is 40-45 and has
the same frequency in both sexes.
Approximately 95% of cases result from
the pituitary adenomas (1). 
Liver cirrhosis is defined chronic
injury of the liver results in inflammation,
necrosis and, eventually, fibrosis. Viral
infections such as hepatitis B and C are
the most common causes of liver cirrhosis
all over the world. Patients with cirrhosis
are at risk of developing many potential
complications. The most common
complication seen in patients with liver
cirrhosis is ascites, and the most lethal one
is bleeding varices (2). 
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There is no previous report of
acromegaly together with liver cirrhosis,
in the literature. The aim of this study was
to report a very rare combination of
acromegaly with cirrhosis in a patient.
CASE REPORT
A 62-year old male patient with
complaint of abdominal distension was
admitted to our clinic (Fig.1). The patient
stated that he had complaining of
abdominal swelling for 6 months. In the
last two weeks the swelling in the legs and
feet, shortness of breath and insomnia
have been added to the clinical findings.
Initial examination revealed diffuse
abdominal ascites and pretibial edema.
Physical examination revealed findings
suggestive of acromegaly, including
coarse facial features and enlargement of
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Figure 1. Severe ascites of the acromegalic patient with liver cirrhosis. 
Figure 3. Acromegalic hand:
characteristic enlarged hand of the
patient, fingers are widened, thickened
and stubby, and the soft tissue is
thickened 
Figure 2. Acromegalic face: pronounced
mandibular prognathism, widened and
thickened nose, prominent supraorbital
ridges, thick and coarsened lips and marked
facial lines. 
his face, hands and feet (Fig. 2-3). There
was no previous history of other feature.
Laboratory findings at admission and 6
months follow- up are summarized in the
Table 1.
No hepatic or gastrointestinal
Acromegaly and cirrhosis
121
Table 1. Laboratory findings, hormone profiles and hepatitis markers of the
acromegalic patient with cirrhosis and reference values
At admission Follow up 
(6 months later)
Reference
Glu (mg/dL)    87                289              80 - 115
Cr (mg/dL)    0,6 1,05 0.7 - 1.2
Na (mmol/L)    141 136 136 - 145
K (mmol/L)    4 4,1 3.5 - 5.1
Tbil (mg/dL)     2,39 2,28 0.2 - 1.2
Dbil (mg/dL)     1,06 1,25 0 - 0.5
Prot (g/dL)      6,3 5,8 6 - 8 
Alb (g/dL)      2,8 2,3 3.5 - 5
AST (IU/L)      104 114 5 - 35
ALT (IU/L)      83 86 10 - 50
Wbc (K/µL)      4.37   4.35            3.6 - 9.4
Hgb (g/dL)      11.9 10,2              13 - 17.5
Plt (K/µL)      47.9 49,8               142 - 424     
PT %62 %34 70 - 130       
HBsAg (S/CO)      > 250.00 > 250.00 < 0.9           
Anti HBs (mIU//mL)    2.06 2.06 < 7              
GH  (ng/mL)                 15.4              51,4          0 - 1            
IGF-1 (ng/mL)              50.3              71,7 71-290
Figure 4. Sagittal T1- weighted MRI image of the pituitary. A tumor (arrow) is
visible in and on the sella turcica. The mass is hyperintense compared to the brain
parenchyma. The normal posterior pituitary “bright” signal is not seen. 
tumors were detected at the liver
ultrasound. The result of laboratory
investigations was hepatitis-B induced
liver cirrhosis. Because of high GH
level, pituitary MR was taken on and
adenoma 1 cm in diameter was detected.
The surgery was not considered to
patient, because of bleeding
complications resulting from cirrhosis.
Medical treatment was recommended
but patients did not accept any
treatment, for that reason follow-up was
advised.
DISCUSSION
Acromegaly is a rare, insidious, and
potentially life-threatening condition for
the patient (3). The most important assays
used for the diagnosis, management, and
monitoring of acromegaly are GH and
IGF-1 measurements (4). GH and IGF-1
levels are generally closely correlated in
patients with acromegaly (5); however,
discordance between GH and IGF-1
levels has been noted in some patients
with acromegaly after treatment (6). IGF-
1 is produced primarily by the liver as an
endocrine hormone as well as in target
tissues in a paracrine/autocrine fashion.
Production is stimulated by GH and can
be retarded by undernutrition, growth
hormone insensitivity, lack of growth
hormone receptors, or failures (7). Most
discordance involves the measurement of
normal GH levels and elevated IGF-1
levels, but some cases exhibit elevated
GH levels and normal IGF-1 levels (6, 8).
In this case, because of hepatic failure
(which can impair IGF-1 production by
the liver) IGF-1 level was below the
normal level at admission and normal
after 6 weeks follow-up. 
The major comorbidities
associated with acromegaly are
cardiovascular disease, diabetes,
hypertension, sleep apnea, arthritis, and
metabolic bone disorders (osteoporosis)
(9). A serious problem in patients with
acromegaly is increased risk of
colorectal and thyroid cancer (10). In
present case, at the clinical examination
acromegalic hands and face were
observed together with ascites.
However, low IGF-1 level, high GH
level was suspected for acromegaly.
After MR examination pituitary
adenoma was diagnosed. There is no
previous report about acromegaly and
cirrhosis association. 
Major complications of cirrhosis
include ascites, spontaneous bacterial
peritonitis, hepatic encephalopathy,
portal hypertension, variceal bleeding,
and hepatorenal syndrome (11).
Hepatitis B incidence is increasing
rapidly in developing countries. At the
50% of untreated patients is progress to
chronic liver disease. The most common
complaint of these cases is ascites (12).
Our patient’s major complaints were
abdominal distension and ascites. These
signs were classical suspected findings
of cirrhosis. Laboratory investigations
supported the diagnosis. 
Patients with hepatitis are at
increased risk of hepatocellular
carcinoma (10). Acromegaly may
accelerate the risk of cancer. Treatment
was advised for both acromegaly and
cirrhosis but the patient did not accept
any treatment and close monitoring was
recommended (13).
Acromegaly is not a common
disease in human and cirrhosis
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generally associated chronic liver
diseases. In this case, patient’s
complaints were related to cirrhosis. At
the clinical examination, acromegaly
was diagnosed. This is the first case
which shows acromegaly and cirrhosis
together in a person.
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